• 
  Promesa y Esperanza® Broadcast Rallies Hispanic Media, Artists, and Fans to Support St. Jude Children's Research Hospital30 December 2025, 10:57 pm

  MEMPHIS, Tenn.--(BUSINESS WIRE)--The St. Jude Promesa y Esperanza® (Promise and Hope) broadcast earlier this month brought together Hispanic media leaders, Latin music artists, and Spanish-speaking audiences to support research and treatment at St. Jude Children’s Research Hospital®. The event, part of the Music Gives to St. Jude Kids initiative, raised $5.2 million. Spanish-language media outlets, including Uforia, iHeart, and Latino Media Group, mobilized radio stations across 15 major market

• 
  Biobeat Secures $50 Million Series B Financing to Advance Commercialization of its Patch-worn, Cuff-less 24-hour Ambulatory Blood Pressure Monitor30 December 2025, 9:39 pm

  PETAH TIKVA, Israel & BOCA RATON, Fla.--(BUSINESS WIRE)-- #24hourABPM--Biobeat closed a $50M Series B, led by Ally Bridge, OrbiMed, and Elevage, to expand U.S. commercialization of its 24 hour FDA-cleared ABPM.

• 
  NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors30 December 2025, 12:05 pm

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of John P. “Jack” Kenny to its Board of Directors.

• 
  Akumin Announces Agreement that will Solidify Long-Term Financial Foundation to Support Continued Growth and Patient Care23 December 2025, 9:00 pm

  PLANTATION, Fla.--(BUSINESS WIRE)--Akumin Inc. (together with its subsidiaries “Akumin” or the “Company”) announced today that it entered into an agreement (the “Support Agreement”) with certain noteholders representing over 95% of outstanding senior secured notes due in 2027 and 2028 (together, the “Senior Secured Notes”), and Stonepeak, a leading alternative investment firm, that will reduce debt, enhance liquidity and extend its debt maturities related to the Senior Secured Notes. Under the

• 
  FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23 December 2025, 5:07 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate

• 
  VOKA Announces Free 1-Month Access to a Pro Subscription for New Users23 December 2025, 1:00 pm

  ST. PETERSBURG, Fla.--(BUSINESS WIRE)-- #3DAnatomy--VOKA provides one-month free access to VOKA 3D Anatomy & Pathology, a high-precision 3D atlas for medical education and clinical professionals.

• 
  National Beverage Advocates Giving the Children of St. Jude . . . ‘A Chance at a Lifetime’18 December 2025, 3:00 pm

  FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Commemorating its 32nd year as a continuing partner of St. Jude Children’s Research Hospital®, National Beverage Corp. (NASDAQ: FIZZ), advocates unconditional support of St. Jude’s mission to advance cures, and means of prevention, for pediatric catastrophic diseases through research and treatment. “The philosophy driving St. Jude is ‘Every child deserves a chance to . . . live.’ I personally am grateful that for more than 30 years, God has blessed me wit

• 
  Smart Meter Introduces First Handheld Cellular-Connected Thermometer for Effortless Patient Monitoring18 December 2025, 2:00 pm

  TAMPA, Fla.--(BUSINESS WIRE)--Smart Meter, the leader in cellular-enabled remote patient monitoring (RPM) solutions, is proud to announce the launch of the first handheld, fully cellular-enabled thermometer. Designed to capture and transmit temperature data in real time, it works directly over cellular networks, with no need for a hub, Wi-Fi, or Bluetooth. This breakthrough makes remote patient monitoring faster, simpler, and more reliable for both providers and patients. The new device is call

• 
  A.R.I. Founder Dr. Zack Ellison Earns Doctorate from the University of Florida Establishing Landmark Venture Debt Research17 December 2025, 5:06 pm

  TAMPA, Fla. & ST. PETERSBURG, Fla.--(BUSINESS WIRE)-- #ARI--Applied Real Intelligence (“A.R.I.”), a leading provider of growth credit and venture debt to North American innovators, announced today that its Founder and Managing General Partner, Dr. Zack Ellison, has earned a Doctor of Business Administration (DBA) from the University of Florida’s Warrington College of Business. His doctoral research, Venture Debt: An Empirical Study of Loan-Level Pricing and Stock-Level Performance, establishes the fir

• 
  Publix Pharmacy Is Now Providing Customers With a Prescription Savings Finder17 December 2025, 4:57 pm

  LAKELAND, Fla.--(BUSINESS WIRE)--Publix launched a new prescription savings finder tool to help customers save money on prescription medications. Discount Finder, powered by RxSense, is now available on the Publix Pharmacy app or by visiting publix.com/rxsavings. The Discount Finder provides customers with a quick and easy way to find lower prices on most prescriptions at Publix Pharmacy. “Discount Finder is a digital marketplace that provides a single location for customers to search for savin

• 
  Voloridge Health Announces Sponsorship of World Champion Speed Skater Jordan Stolz17 December 2025, 3:55 pm

  JUPITER, Fla.--(BUSINESS WIRE)--Voloridge Health, LLC, a data science company dedicated to empowering individuals and organizations to transform health with data-driven insights, is proud to announce a strategic partnership with World Champion speed skater Jordan Stolz. At just 21 years old, Stolz has quickly established himself as one of the most dominant figures in long track speed skating. The current world record holder in the 1000m, he captured the 2024 World Allaround Championships to bec

• 
  Biocerta Precision Diagnostics Announces Exclusive Licensing Agreement With the University of Miami and Strategic Development Partnership With Acumen Partners17 December 2025, 2:15 pm

  PITTSBURGH--(BUSINESS WIRE)-- #cancer--Biocerta Precision Diagnostics, Inc., a biotechnology company pioneering functional drug sensitivity testing (DST) to personalize cancer therapy, today announced two major business milestones: (1) an exclusive licensing agreement with the University of Miami covering core intellectual property assets which contribute to Biocerta’s DST technology, and (2) a strategic development and commercialization agreement with Acumen Partners to support the Company through early

• Cardone Ventures Announces Unsolicited $4.25 Per Share All-Cash Proposal to Acquire PetMed Express16 December 2025, 5:04 pm

  MIAMI--(BUSINESS WIRE)--Cardone Ventures, backed by billionaire investor, Grant Cardone and his business partners Brandon and Natalie Dawson, today announced that it has submitted an unsolicited, non-binding proposal to acquire PetMed Express, Inc. (Nasdaq: PETS) (“PetMeds”) for $4.25 per share in cash, representing an implied equity value of approximately $89 million. The proposal was delivered to the Board of Directors of PetMed Express and is not subject to any financing contingency, reflect

• 
  Kalogon Opens $50M Production Facility, Expands Team as Revenue Doubles16 December 2025, 2:00 pm

  MELBOURNE, Fla.--(BUSINESS WIRE)--Smart seating leader Kalogon has expanded to a dedicated manufacturing facility with a $50 million production capacity following revenue growth.

• 
  Reimagine Care and Tampa General Hospital Cancer Institute Launch Virtual Cancer Care Collaboration to Reduce Hospitalizations and Elevate Patient Support16 December 2025, 1:00 pm

  NASHVILLE, Tenn. & TAMPA, Fla.--(BUSINESS WIRE)--Reimagine Care, the leader in on-demand, technology-enabled cancer care, today announced a collaboration with the Tampa General Hospital (TGH) Cancer Institute to expand access, increase clinical capacity and improve cancer care delivery across the Tampa Bay region. The partnership integrates Reimagine Care’s AI-enabled virtual cancer care program into Tampa General’s clinical pathways, supporting the Institute’s long-term strategy to scale oncol

• 
  Algia Pharma Gains FDA Support to Advance Novel Non-Opioid Pain Treatment Toward a Phase 2 Clinical Trial After IND-Enabling Studies With Indication Expanded to All Mild-to-Moderate Acute Pain15 December 2025, 12:30 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--Algia Pharma, LLC (“Algia”) today announced the company has received support from the U.S. Food and Drug Administration (FDA) to advance AlgiaPak® toward a Phase 2 clinical trial upon completion of Investigational New Drug (IND)-enabling studies. AlgiaPak is the company’s streamlined, multimodal pain formulation designed to treat all mild-to-moderate acute pain as effectively as opioids, without exposing patients to the risk of opioid addiction. The company ha

• 
  NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation15 December 2025, 12:05 pm

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced that Natera has voluntarily withdrawn its appeal in ongoing RaDaR patent litigation.

• 
  26Health Expands Partnership with NuvemRX to Open First Entity-Owned Pharmacy11 December 2025, 2:00 pm

  SHARON HILL, Pa.--(BUSINESS WIRE)--26Health, a Central Florida-based family health center committed to providing comprehensive care to underserved communities, today announced plans to open its first entity-owned pharmacy in Orlando. This initiative is being made possible through an expansion of the health center’s partnership with NuvemRx, a leading tech-enabled pharmacy service for community health providers. Healthcare providers often face significant challenges in standing up and optimizing

• 
  NeoGenomics to Present New ctDNA Research at SABCS 202510 December 2025, 12:05 pm

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present data on its RaDaR 1.0 assay for molecular residual disease detection at the 2025 San Antonio Breast Cancer Symposium.

• 
  Kelonia Therapeutics Presents First-in-Human Data From Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting9 December 2025, 12:30 pm

  BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today shared first-in-human data from the ongoing inMMyCARTM study, a Phase 1 clinical trial evaluating KLN-1010, a novel in vivo gene therapy that generates anti-BCMA CAR-T cells in patients with relapsed and refractory multiple myeloma, in a late-breaking oral presentation at the American Society of Hematology (ASH) 2025 Annual Meeting in Orlando, Florida. Highlights o

• 
  O.N.E Amazon calls for biodiversity to be treated as critical global infrastructure at the Nobel Sustainability Trust Summit 20259 December 2025, 12:03 am

  MIAMI--(BUSINESS WIRE)--O.N.E Amazon calls for biodiversity to be treated as critical global infrastructure at the Nobel Sustainability Trust Summit 2025

• 
  From Novel Therapies to First-in-Human Trials, City of Hope Advances Blood Cancer Care at the American Society of Hematology (ASH) Annual Conference8 December 2025, 10:30 pm

  LOS ANGELES--(BUSINESS WIRE)--Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation’s top cancer centers by U.S. News & World Report, presented scientific results on novel therapies, treatment strategies, and approaches to managing side effects and complications for blood cancer patients at the 2025 American Society of Hematology (ASH) conference in Orland

• 
  Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia8 December 2025, 9:30 pm

  WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Updated Positive Data at ASH 2025 Reinforce the Potential of Incyte's INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in ET

• 
  Qihan Biotech Presents New Clinical Data on Allogeneic CAR-T Cell Therapies and Preclinical Data on In Vivo CAR-T at the American Society of Hematology (ASH) Annual Meeting8 December 2025, 9:30 pm

  ORLANDO, Fla.--(BUSINESS WIRE)--Qihan Biotech, a clinical-stage biotechnology company developing off-the-shelf cell therapies for autoimmune diseases and cancer, including allogeneic CAR-T and in vivo CAR-T therapies, presented an oral and several poster presentations at the 67th American Society of Hematology (ASH) Annual Meeting. The data included encouraging clinical results with the company’s allogeneic CAR-T program and foundational preclinical work supporting its emerging in vivo CAR-T pr

• 
  Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)8 December 2025, 9:30 pm

  COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE® CLL-1 trial (NCT04623541) evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy and in combination for the treatment of patients with Richter transformation (RT), a rare complication in which chronic lymphocytic leukemia (CLL) evolves into an aggressive lymphoma

• 
  Abcuro Presents Interim Phase 1 Data Evaluating Ulviprubart in Patients with T Cell Large Granular Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting8 December 2025, 5:00 pm

  NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a late-stage clinical biotechnology company developing potentially first-in-class immunotherapies designed to benefit people living with debilitating and progressive rare autoimmune diseases and for other indications where certain cytotoxic T cells are pathogenic, today presented interim data from the ongoing Phase 1/2 clinical trial evaluating ulviprubart (ABC008) in patients with T cell large granular lymphocytic leukemia (T-LGLL) with anemia and/

• 
  MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival8 December 2025, 5:00 pm

  LYON, France--(BUSINESS WIRE)---- $MAAT #ASH--MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival.

• 
  Genetix Presents Recent Patient Experience Data from U.S. Commercial Gene Therapy Implementation at the 67th American Society of Hematology (ASH) Annual Meeting8 December 2025, 2:30 pm

  SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc. today announced real-world data from the commercial implementation of ZYNTEGLO™ and LYFGENIA™, first-in-class ex vivo gene addition therapies for the treatment of beta-thalassemia and sickle cell disease. With over 250 patients treated with these therapies, inclusive of clinical trials and commercial treatments, and long-term follow-up data beyond 10 years, Genetix has the most robust long-term dataset in ex vivo gene therapy for

• 
  Opna Bio Showcases Multi-Functional Degraders with Potent Anti-Myeloma Activity and Encouraging Spleen Reductions in Patients with Myelofibrosis Treated with OPN-2853 and Ruxolitinib8 December 2025, 2:00 pm

  ORLANDO, Fla.--(BUSINESS WIRE)--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced promising preclinical data from the company’s novel, multi-functional protein degrader program and positive updated data from an ongoing Phase 1 combination study with OPN-2853, a bromodomain and extra-terminal motif (BET) inhibitor, as an add-on to ruxolitinib in patients with advanced myelofibrosis. Data were shared in an oral

• 
  NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 20258 December 2025, 1:05 pm

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present new data at ASH on how comprehensive genomic profiling supports diagnosis and treatment decisions in myeloid malignancies.

• 
  BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia8 December 2025, 1:00 pm

  SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth, quality, and momentum of its hematology portfolio at the 67th ASH Annual Meeting and Exposition in Orlando, Florida. The totality of BeOne’s ASH data reinforce BRUKINSA® (zanubrutinib) as the foundational Bruton’s tyrosine kinase inhibitor (BTKi) of choice. “At

• 
  Orum Therapeutics Presents Preclinical Data at ASH 2025 Demonstrating Potent and Selective Antitumor Activity of ORM-1153, a CD123-Targeting Degrader Antibody Conjugate for Acute Myeloid Leukemia8 December 2025, 1:00 pm

  BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)-- #ADC--Orum Therapeutics Presents Preclinical Data at ASH 2025 Demonstrating Potent and Selective Antitumor Activity of ORM-1153 for Acute Myeloid Leukemia

• 
  Children’s Hospital Los Angeles Researchers Identify Markers at Birth Linked to Childhood Leukemia Risk8 December 2025, 12:00 pm

  LOS ANGELES--(BUSINESS WIRE)--A new study led by Children’s Hospital Los Angeles has linked specific molecular markers at birth to future childhood leukemia risk.

• 
  Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies7 December 2025, 11:00 pm

  SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses

• 
  Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA7 December 2025, 2:30 pm

  WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

• 
  Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 20257 December 2025, 2:30 pm

  WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with MF Presented at ASH 2025

• 
  Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma7 December 2025, 12:50 pm

  COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced primary data from the pivotal Phase 3 EPCORE® FL-1 study evaluating fixed duration EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) in adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The study showed that treatment with EPKINLY + R2 reduced the risk of disease progression or death by 79% (HR 0.21, 95% CI: 0.14-0.31, p<0.0001) compared to standard

• 
  HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors6 December 2025, 10:15 pm

  NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The results demonstrated the superiority of HYMPAVZI in improving key bleeding outcomes compared to on-demand (OD) treatment with bypassing agents. HYMPAVZI was administered with a straightforward, once-weekly subcutaneous injection requiring minimal preparation and no tr

• 
  Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6 December 2025, 2:30 pm

  OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. The results were presented by Ionis Pharmaceuticals

• 
  Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)6 December 2025, 2:30 pm

  COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced updated results from two ongoing clinical trials evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging antibody administered subcutaneously, as a monotherapy and in combination with other standard of care treatments in adult patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Results from two arms of the EPCORE® NHL-2 trial, evaluating first-line, fixed-treatment dur

• 
  NMDP℠ Demonstrates Scientific Leadership in Expanding Patient Access to Lifesaving Cell Therapy at ASH 20256 December 2025, 1:35 pm

  MINNEAPOLIS--(BUSINESS WIRE)--New research from NMDP, a global nonprofit leader in cell therapy, and conducted by CIBMTR® (Center for International Blood and Marrow Transplant Research®) at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla., demonstrates that patients receiving allogeneic transplantation using more deeply mismatched unrelated donors (MMUD), followed by post-transplant chemotherapy, can achieve outcomes comparable to those receiving tran

• 
  Genetix Participates in the American Society of Hematology’s (ASH) Exclusive Press Program &amp; Shares Recent Patient Experience Data from U.S. Commercial Gene Therapy Implementation6 December 2025, 12:05 pm

  SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc. today announced their participation in the American Society of Hematology’s (ASH) exclusive press program ahead of the 67th ASH annual meeting in Orlando, Florida (December 6-9, 2025). Genetix’s abstract Accelerating access to gene therapy: Lessons from commercial implementation in sickle cell disease and transfusion-dependent thalassemia was selected by the ASH Program Committee as one of the meeting’s most impactful datasets sub

• 
  Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5 December 2025, 9:30 pm

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 67,483 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committe

• 
  CONMED Corporation Announces Strategic Exit from Gastroenterology Product Lines5 December 2025, 1:00 pm

  LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its intention to exit its gastroenterology product lines as part of its broader portfolio optimization strategy. This exit allows CONMED to fully align operations and resources within its core markets—minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and the surgical treatment of orthopedic soft tissue repair. “Today’s announcement reflects a positive step in our strategic portfolio review and o

• 
  Ossium Health to Present New Clinical Data on Its Organ Donor Bone Marrow at ASH 20255 December 2025, 10:00 am

  SAN FRANCISCO--(BUSINESS WIRE)--Ossium Health will present new clinical outcomes data at ASH 2025, highlighting the potential of organ donor bone marrow as a promising graft source.

• 
  Introducing Outcomes Insights: A New Standard for Pharmacy Intelligence4 December 2025, 8:00 pm

  ORLANDO, Fla.--(BUSINESS WIRE)--Outcomes® is formalizing the availability of Outcomes Insights, an advanced reporting platform that provides pharmacies with comprehensive visibility into their performance. Currently exclusive to Rx30 users, the solution equips teams with actionable intelligence to enhance operational efficiency and business health. “Outcomes Insights represents a major step forward in helping pharmacies unlock actionable intelligence,” said Jon Grice, VP, Pharmacy Insights for

• 
  Mission Bio’s Tapestri Single Cell Multi-Omics Platform for Exploratory Biomarker Analysis Supports Myeloproliferative Neoplasms (MPNs) Data Presentation at ASH 20254 December 2025, 2:00 pm

  SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mission Bio, Inc., a leader in single-cell multi-omic solutions for precision medicine, announced that its Tapestri Platform and custom assay development supported initial exploratory biomarker analysis data presented by Incyte at the ASH 2025 conference in Orlando, Florida, in December. The data demonstrate Tapestri® Platform’s ability to accelerate the understanding of Myeloproliferative Neoplasms (MPNs) disease biology at the single-cell level. M

• 
  Arima Genomics Reports New Data at ASH 2025 Supporting More Complete Rearrangement Profiling in DLBCL With Hi-C Technology Used in Aventa Lymphoma4 December 2025, 1:00 pm

  CARLSBAD, Calif.--(BUSINESS WIRE)-- #ASH--Arima Genomics, a company leveraging whole-genome sequence and structure information, today announced new data to be presented at ASH.

• 
  AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH4 December 2025, 12:00 pm

  WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to redefine hematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6-9, 2025. This year’s ASH congress will feature the Company’s largest presence to date, with 65 abstracts across eight approved and investigational medicines, including 15 oral presentations. Key presentations include: Phase I trial of surovatamig: Updated r

• 
  Vycellix Prepares for First-in-Human Study of Novel Allogeneic Cell Therapy Powered by Its Universal Cell Engineering Platform3 December 2025, 5:00 pm

  BOCA RATON, Fla. & STOCKHOLM--(BUSINESS WIRE)-- #ASH25--Vycellix advancing breakthrough discovery to human study with aim to redefine paradigm for transplant medicines, eliminating risk of graft rejection.

• 
  Catalyst OrthoScience Receives FDA 510(k) Clearance for Expanded Indications of the Fracture Shoulder System3 December 2025, 3:00 pm

  NAPLES, Fla.--(BUSINESS WIRE)--Expanded indications provide surgeons flexibility for better patient outcomes, reinforcing Catalyst’s role as a leader in next-gen shoulder solutions.

• 
  New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting3 December 2025, 1:00 pm

  AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced that new data on Signatera will be presented at the 2025 American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, Florida. Natera and its collaborators will present four abstracts highlighting the clinical validity and utility of Signatera in hematologic malignancies. The datasets include an oral presentation on a retrospective

• 
  New Family Heart Foundation Study Finds Only 13% of Adults With Cardiovascular Disease Achieve Comprehensive LDL-C Management3 December 2025, 1:00 pm

  FERNANDINA BEACH, Fla.--(BUSINESS WIRE)--The Family Heart Foundation, a leading research and advocacy organization, published new research in the American Journal of Preventive Cardiology revealing significant gaps in cholesterol management during 2022-23 among U.S. adults with atherosclerotic cardiovascular disease (ASCVD). Findings show that only 13% of adults with ASCVD were meeting three key components of optimal low-density lipoprotein-cholesterol (LDL-C) management, including receiving gu

• 
  Trividia Health, Inc. Announces Preferred Listing of the TRUE METRIX® Blood Glucose Meters and Test Strips on the Express Scripts Commercial National Preferred Formulary2 December 2025, 5:33 pm

  FT. LAUDERDALE, Fla.--(BUSINESS WIRE)-- #TRUEMETRIX--Trividia Health, Inc., announced today that it’s TRUE METRIX® Self-Monitoring Blood Glucose Systems are preferred for commercial patients on the Express Scripts National Preferred Formulary in the United States, effective October 1st, 2025. The TRUE METRIX® portfolio provides a level of performance rooted in science, research and technological advancements. TRUE METRIX test strips feature TRIPLE SENSE TECHNOLOGY®, which ensures proven accuracy and confiden

• 
  ILiAD Biotechnologies Announces Lancet Microbe Publication of BPZE1 Phase 2b Clinical Results in Human Challenge Model2 December 2025, 3:05 pm

  WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella Pertussis, today announced the peer-reviewed publication of Phase 2b trial results in The Lancet Microbe (Link). The published research article summarizes the CHAMPION-1 clinical study of BPZE1, a randomized, double-blind, placebo-controlled study conducted in healthy adults in a controlled human infection model. BP

• 
  CytoAgents Announces Poster Presentation of New CTO1681 Clinical Data at the 67th American Society of Hematology Annual Meeting2 December 2025, 2:05 pm

  PITTSBURGH--(BUSINESS WIRE)-- #ASH25--CytoAgents announced a poster presentation of new CTO1681 clinical data at the 67th American Society of Hematology Annual Meeting.

• 
  Findings from Ontada’s Real-World Study: Maintaining Hemoglobin Levels &gt;10 g/dL in Patients with Myelodysplastic Syndrome is Associated with Significantly Improved Overall Survival2 December 2025, 1:15 pm

  BOSTON & ORLANDO, Fla.--(BUSINESS WIRE)--Ontada®, a McKesson business dedicated to real-world oncology data and insights, will present findings from a retrospective cohort study at ASH 2025.

• 
  Sarah Cannon Research Institute to Present Research on Advances in Blood Cancers and Blood Disorders at 2025 ASH Annual Meeting &amp; Exposition2 December 2025, 1:00 pm

  NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, announced today that it will showcase its latest research through 100 abstracts and presentations at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place in Orlando, Florida and virtually from December 6-9. SCRI’s expansive network is represented by more than 50 researchers who ser

• 
  Genomic Testing Cooperative (GTC) to Share 12 Ground-breaking Abstracts at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando2 December 2025, 12:00 pm

  LAKE FOREST, Calif.--(BUSINESS WIRE)--Genomic Testing Cooperative (GTC), a leading provider of integrated DNA and RNA next-generation sequencing (NGS) solutions for hematologic tumors and liquid biopsy applications, today announced that its work and data will be presented in 12 abstracts at the ASH 2025 Annual Meeting in Orlando, December 6-9. The work represents novel proprietary approaches using artificial intelligence (AI) for prediction models, transcriptomic signatures, cell-free RNA (cfRN

• 
  Owens &amp; Minor to Present at Upcoming Investor Conferences on December 2, 20252 December 2025, 12:00 pm

  RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) announced today that members of its management team are scheduled to participate in two upcoming investor conferences. Citi 2025 Global Healthcare Conference On Tuesday, December 2, 2025, Ed Pesicka, the Company’s President and Chief Executive Officer, and Will Parrish, the Company’s Vice President of Strategy, Corporate Development, & Investor Relations, are scheduled to participate in a fireside chat at 2:30 P.M. ET and h

• 
  Akumin Expands Akumin AXIS™ Line with New 1.5T MRI and Akumin AXIS Drop Trailer1 December 2025, 6:00 pm

  PLANTATION, Fla.--(BUSINESS WIRE)-- #Akumin--Akumin today announced the debut of two major advancements in its Akumin AXIS™ line of relocatable imaging suites at the 2025 Radiological Society of North America (RSNA) annual meeting. The company unveiled the Akumin AXIS 1.5T MRI and introduced the Akumin AXIS Drop Trailer (patent-pending), the first design of its kind in the U.S. and a new evolution in Akumin’s industry-leading mobile imaging portfolio. Together, these new configurations highlight Akumin’s

• 
  Kaplan Survey: Nearly 9 in 10 Medical Schools Expect Fierce Competition Again This Admissions Cycle1 December 2025, 1:55 pm

  FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #doctors--Kaplan survey: 89 percent of medical school admissions officers say aspiring doctors are in the midst of another highly competitive admissions cycle.

• 
  Nuvation Bio to Participate in Upcoming Investor Conferences26 November 2025, 9:05 pm

  NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats at two upcoming investor conferences: 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 9:35 a.m. ET in Miami, FL

• 
  Smart Meter Opinion Editorial: Remote Patient Monitoring Works. UnitedHealthcare’s 2026 Rollback Ignores the Evidence, and Patients Will Pay the Price.26 November 2025, 2:00 pm

  TAMPA, Fla.--(BUSINESS WIRE)--The following is an opinion editorial provided by Casey Pittock, CEO, Smart Meter: UnitedHealthcare’s decision to sharply limit remote patient monitoring (RPM) reimbursement beginning January 1, 2026, to heart failure and hypertensive disorders of pregnancy, is a disservice to clinicians, patients, and the healthcare system at large. It contradicts federal momentum to modernize chronic care and misrepresents the weight of current evidence on RPM’s clinical value fo

• 
  Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting26 November 2025, 1:30 pm

  SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented exploratory data at The Menopause Society 2025 Annual Meeting in Orlando, Florida. These findings demonstrate PH80’s potential as a rapidly-acting pherine product candidate for treating vasomotor symptoms (hot flashes) du

• AdaptHealth Corp. to Participate in Upcoming Investor Conference26 November 2025, 1:30 pm

  CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that they will participate in the BofA Securities Leveraged Finance Conference, being held in Boca Raton, FL, on Tuesday, December 2, 2025, including a fireside chat at 8:10 a.m. ET. The webcast link will be available on the Com

• 
  U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma26 November 2025, 11:00 am

  SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase (BTK) inhibitor. “Sonrotoclax is a

• 
  Former Latin American Presidents Join Experts for High-Level Panel on Future Health Preparedness25 November 2025, 3:00 pm

  MEXICO CITY--(BUSINESS WIRE)-- #COVID19--The AHF Global Public Health Institute for Latin America and the Caribbean, in collaboration with the University of Miami Public Health Policy Lab, invites members of the press to a high-level virtual panel titled “Why Should Latin America Act as a Bloc in Future Health Emergencies? Toward a Common Regional Preparedness and Response Agenda.” Latin America has been among the regions most affected by recent health crises—including the COVID-19 pandemic and the 2024 d

• 
  Evercore Hosts 8th Annual Healthcare Conference, Dec. 2-4, 202525 November 2025, 1:00 pm

  NEW YORK--(BUSINESS WIRE)--Evercore (NYSE: EVR) will host its 8th annual Healthcare Conference at the Loews Coral Gables Hotel in Coral Gables, Florida, Dec. 2-4, 2025. This year’s conference features over 500 industry experts and corporate leaders from more than 200 leading healthcare companies. Across three days, guests will have the opportunity to attend panels, fireside chats, scheduled investor meetings and company-hosted dinners while directly engaging with key industry professionals. The

• 
  CAN Community Health Presents World AIDS Day Concert Featuring Broadway Legends Adam Pascal &amp; Anthony Rapp25 November 2025, 1:00 pm

  FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #PrEP--CAN Community Health is proud to present its 2025 World AIDS Day Concert, an inspiring night of remembrance, resilience, and community, headlined by Tony-nominated Broadway icons Adam Pascal and Anthony Rapp, original stars of the groundbreaking musical RENT. The event, presented by ViiV Healthcare, will take place Sunday, November 30 at Las Olas Oceanside Park, marking South Florida’s largest World AIDS Day observance. For nearly 35 years, CAN Community

• 
  Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences25 November 2025, 1:00 pm

  HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the company’s management team will participate in two upcoming conferences. 8th Annual Evercore Healthcare Conference Date: December 2, 2025 Time: 8:45-9:05 am ET Format: Fireside Chat Participant: Dr. Arun Swaminathan, Ph.D., Chief

• 
  Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference25 November 2025, 12:30 pm

  BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:25 am ET in Miami, Florida. A live webcast of the fireside chat can be accessed under “Events & Presentations” on the Company’s website at www.vera

• 
  Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference25 November 2025, 12:00 pm

  CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 8th Annual Evercore Healthcare Conference in Miami. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat on Tuesday, December 2, at 7:55 a.m. ET and host investor meetings. A webcast of the p

• 
  Kelonia Therapeutics Announces Late-Breaking Oral Presentation of First-in-Human Data from in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting24 November 2025, 5:00 pm

  BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced that its first results from the ongoing inMMyCAR study, a Phase 1 clinical trial evaluating KLN-1010, a novel in vivo gene therapy that generates anti-BCMA CAR-T cells in patients with relapsed and refractory multiple myeloma, will be presented in a late-breaking oral presentation at the American Society of Hematology (ASH) 2025 Annual Meeting in Orlando,

• 
  Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches24 November 2025, 11:45 am

  RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla. from Dec. 6-9. The data shared at the meeting will highlight the company’s ongoing commitment to advancing clinical research in hematology across Merck’s expanding and diverse pipeline of investigational candidates,

• 
  Imperative Care Presents Positive Real-World Data from Ischemic Stroke Patients Treated with ADAPT 2.0 Using the Zoom Stroke System21 November 2025, 9:15 pm

  CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care announces late-breaking, real-world data from a multi-center review of ischemic stroke patients treated with ADAPT 2.0.

• 
  IonQ Leaders to Present at World Strategic Forum20 November 2025, 12:05 pm

  COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), the world’s leading quantum company, today announced its participation at the 14th World Strategic Forum (WSF), taking place November 24–25 at the Loews Coral Gables Hotel in Coral Gables, Florida. The Forum brings together global leaders under the theme “Driving Prosperity through Innovation.” IonQ will highlight how quantum computing, networking, and sensing are poised to unlock new economic value, improve national resilience, and enable

• 
  BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 202520 November 2025, 11:00 am

  SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, advances its vision to become the world’s leading oncology company with extensive new data from its differentiated hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, December 6-9. Nearly 50 abstracts have been accepted, including six oral presentations, featuring the company’s three transformative appr

• 
  Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference19 November 2025, 9:05 pm

  SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3 at 10:50 a.m. ET / 7:50 a.m. PT in Miami, Florida. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.

• Arcus Biosciences to Participate in Two Upcoming Investor Conferences18 November 2025, 9:05 pm

  HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming investor conferences in December: 8th Annual Evercore Healthcare Conference Date: Tuesday, December 2nd, 2025 Location: Coral Gables, FL Format: Fireside chat & 1x1

• 
  Massive Bio Collaborates with the American Cancer Society to Accelerate Equitable Access to Cancer Clinical Trials18 November 2025, 6:17 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio today emphasized the nationwide expansion of ACS ACTS® (Access to Clinical Trials and Support), the American Cancer Society’s program designed to help people across the United States navigate clinical trial options more easily. As the initiative scales, Massive Bio continues its collaboration by providing the AI-powered clinical trial matching technology used within ACS ACTS, helping ensure that individuals receive personalized options sourced thro

• 
  Harmony Biosciences to Participate in Upcoming Investor Conferences18 November 2025, 1:05 pm

  PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Citi's 2025 Global Healthcare Conference Location: Miami, FL Tuesday, December 2, 2025 8th Annual Evercore Healthcare Conference Location: Miami, FL Fireside Chat: Tuesday, December 2, 2025, at 2:35 p.m. ET Piper Sandler 37th Annual Healthcare Conference Location: New York, NY Fireside Chat: Wed

• 
  Akumin Receives Innovative Technology Designation from Vizient for Akumin AXIS™18 November 2025, 1:00 pm

  PLANTATION, Fla.--(BUSINESS WIRE)--Akumin Inc. (“Akumin” or the “Company”), a leader in managed radiology and oncology services, announces their proprietary Akumin AXIS Expandable Patient Solutions™ has received an Innovative Technology designation from Vizient® the largest healthcare performance improvement company in the country. Akumin exhibited their PET/CT, MRI and LINAC configured Akumin AXIS Solutions at the Vizient Innovative Technology Exchange September 17 in Las Vegas. Each year, hea

• 
  PharmaEssentia Announces Presentations at ASH 202518 November 2025, 1:00 pm

  BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced it will be presenting at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9 in Orlando, Florida. The Company’s presentations will share new data exploring t

• 
  Scholar Rock to Present at Upcoming Investor Conferences18 November 2025, 1:00 pm

  CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in the following investor conferences: Citi 2025 Global Healthcare Conference: Scholar Ro

• Sensus Healthcare Expands Role of President Michael Sardano to Include Chief Commercial Officer14 November 2025, 1:00 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that President Michael Sardano has been appointed to the additional role of Chief Commercial Officer. In this newly created position, Mr. Sardano will direct the company’s global sales, marketing and commercial strategy across its po

• 
  TherapeuticsMD Announces Third Quarter 2025 Financial Results12 November 2025, 9:05 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted

• 
  SOTIO Presents Positive Results from Non-Human Primate Study of SOT106, a Potential Best-in-Class ADC for Treatment of Sarcoma12 November 2025, 2:00 pm

  PRAGUE & BASEL, Switzerland & BOSTON--(BUSINESS WIRE)--SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced favorable preclinical results supporting the development of SOT106, its antibody-drug conjugate for the treatment of sarcoma, at the Connective Tissue Oncology Society (CTOS) Annual Meeting taking place November 12-15, 2025, in Boca Raton, FL. Data presented in SOTIO’s poster indicate that SOT106 is a potent and well-tolerated LRRC15-targeted ADC,

• 
  Natural Immunogenics Corporation Becomes Sovereign Naturals12 November 2025, 2:00 pm

  SARASOTA, Fla.--(BUSINESS WIRE)--Natural Immunogenics Corporation, makers of Sovereign Silver, today announced it has changed its name to Sovereign Naturals. The new corporate identity reflects the company's evolution beyond silver into a broader portfolio of natural wellness solutions. At the same time, Sovereign Silver remains the trusted product line it has been for over 25 years. Since 1999, Natural Immunogenics has pioneered silver hydrosol technology, making Sovereign Silver the #1-sellin

• 
  Oragenics Q3 2025 Shareholder Update12 November 2025, 1:30 pm

  SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today reported key operational, financial, and strategic achievements for the third quarter of 2025. These milestones reflect the Company's evolution from vision to execution as it advances toward critical clinical trial initiation in Q4 2025/Q1 2026. OPERATIONAL EXCELLENCE: FOUNDATION RESTORED N

• 
  Shields Health Solutions and Lakeland Regional Health Collaborate to Enhance Patient Access to Specialty Pharmacy Care12 November 2025, 1:00 pm

  STOUGHTON, Mass. & LAKELAND, Fla.--(BUSINESS WIRE)--Shields Health Solutions (Shields), the premier specialty pharmacy accelerator in the country, has partnered with Lakeland Regional Health, one of Florida’s leading healthcare providers, to improve access to specialty medications for patients managing chronic and complex health conditions. This enhanced collaboration is designed to support patients who rely on specialty medications to treat conditions such as cancer, multiple sclerosis, and au

• Sensus Healthcare Appoints Eric Sachetta to its Board of Directors12 November 2025, 1:00 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Eric Sachetta to the Company’s Board of Directors. Mr. Sachetta is filling the vacancy that resulted from the passing of long-serving Director Bill McCall. Throughout his career, Mr. Sachetta has held a range of le

• 
  Future Cardia and Artella Solutions Announce Strategic Collaboration for Next-Generation Implantable Cardiac Monitoring11 November 2025, 2:47 pm

  HOUSTON & TAMPA, Fla.--(BUSINESS WIRE)--Artella Solutions and Future Cardia announce an expanded strategic collaboration.

• 
  Belenos Pipeline Updates: First Clinical Data from Lead Asset BEL512, a Long-lasting Bispecific Targeting TSLP and IL-13, Second Asset BEL536, a First-in-class Long-acting Bispecific Targeting OX40L and IL-13, Phase 1 to Start 1Q202610 November 2025, 10:54 pm

  SARASOTA, Fla.--(BUSINESS WIRE)--Belenos Biosciences Inc.: BEL512: Support for Extended Dosing Intervals: Subcutaneous BEL512 (CM512) demonstrated long half-life of up to 70 days Clinical Improvements: Patients dosed on Day 1, Day 15, and Day 29 achieved EASI-75 quickly at Week 6 and were maintained for over 12 weeks Key Biomarker Suppression: Key biomarkers of inflammation decreased, including TARC, IgE, IL-13, TSLP, and eotaxin-3 Favorable Safety: Well-tolerated with no safety concerns identi

• 
  New Data Show Early and Consistent Response to VTAMA® (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those With Associated Comorbidities8 November 2025, 1:00 pm

  JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's VTAMA (tapinarof) cream, 1% shows early and consistent response in children 2+ with atopic dermatitis, including with atopic comorbidities.

• 
  Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China7 November 2025, 2:00 pm

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that our partner, Akeso, Inc. (“Akeso,” HKEX Code: 9926.HK) published results from the Phase III HARMONi-A trial, conducted in China and sponsored by Akeso, featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented today as part of the Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2025) in National Harbor, M

• 
  Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease7 November 2025, 2:00 pm

  WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the NATRON Phase III trial showed AstraZeneca’s FASENRA (benralizumab) demonstrated a statistically significant delay in the time to first worsening or flare in hypereosinophilic syndrome (HES),1 a rare disease driven by elevated eosinophils.2 These data will be presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2025 Annual Scientific Meeting in Orlando, Florida. Hypereosinophilic Syndrome (HES) is a group of

• 
  One Equity Partners Exits Investment in InfuCare Rx7 November 2025, 1:00 pm

  NEW YORK--(BUSINESS WIRE)-- #buyback--One Equity Partners announced it has exited its investment in InfuCare Rx, Inc. through a strategic founder-led equity buyback.

• 
  Gossamer Bio to Participate in Upcoming Investor Conferences7 November 2025, 12:31 pm

  SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will participate in the following investor conferences in November. UBS Global Healthcare Conference Date / Time: November 10th Format: 1x1’s Location:

• Sensus Healthcare Reports Third Quarter 2025 Financial Results6 November 2025, 9:05 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months ended September 30, 2025. Highlights of the third quarter of 2025 and subsequent weeks include the following: CMS established coding validating SRT for treating non-melanoma skin cancer Revenu

• 
  Prothena Reports Third Quarter 2025 Financial Results and Business Highlights6 November 2025, 9:05 pm

  DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the third quarter and first nine months of 2025 and provided business highlights.

• 
  Trividia Health, Inc. Announces Preferred Listing of the TRUE METRIX® Blood Glucose Systems on CVS Caremark Commercial Template Formularies6 November 2025, 3:27 pm

  FT. LAUDERDALE, Fla.--(BUSINESS WIRE)-- #TRUEMETRIX--Trividia Health, Inc., announced today that it’s TRUE METRIX® Self-Monitoring Blood Glucose Systems are now preferred for commercial patients on CVS Caremark Commercial Template Formularies in the United States, replacing OneTouch® branded blood glucose monitors and test strips. The TRUE METRIX® portfolio delivers scientifically backed performance built on decades of research and technological innovation. The TRUE METRIX meters and test strips feature TRIP

• 
  Lurex Bio Announces Patent Filings and a New Frontier in Immune Engineering6 November 2025, 2:00 pm

  FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Lurex Bio files provisional patents for next-gen immunotherapy and immune-signal delivery platforms.

• 
  Montai Therapeutics Presents Preclinical Data on NRF2 Agonist in Ulcerative Colitis at ACAAI Annual Meeting6 November 2025, 1:00 pm

  CAMBRIDGE, Mass.--(BUSINESS WIRE)--Montai will present data for the first time on its novel oral NRF2 agonist molecule, MTAI-1025, for ulcerative colitis (UC) during ACAAI in Orlando.

• 
  ReAlta Life Sciences to Present RLS-0071 (pegtarazimod) Clinical Data at 2025 American Society of Hematology Annual Meeting6 November 2025, 1:00 pm

  NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced a poster presentation featuring new RLS-0071 (pegtarazimod) clinical data from its Phase 2 acute graft-versus-host disease (aGvHD) trial at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December

• Sensus Healthcare Named to TIME’s America’s Growth Leaders of 20266 November 2025, 1:00 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that it has been named to TIME’s list of America’s Growth Leaders of 2026, developed in partnership with Statista Inc. The ranking recognizes 500 U.S. publicly traded companies characterized by revenue growth, financial stability and

• 
  Sempresto and Health Alliance Global Partner to Develop a Smart Communication Platform Integrating Patientside Diagnostics and Virtual Care with Rescue Medication Delivery6 November 2025, 1:00 pm

  JACKSONVILLE, Fla. & BOSTON--(BUSINESS WIRE)--Health Alliance Global, Inc. (Heal All), a leader in patientside diagnostic technologies and virtual care services staffed 24/7/365 by emergency medicine clinicians, and Sempresto, Inc., a Boston-based medical technology company developing smartphone-integrated rescue drug delivery devices, today announced a strategic collaboration to provide on-demand access to qualified medical providers in acute emergency situations to improve patient outcomes an

• 
  NeoGenomics to Participate in Upcoming Investor Conferences6 November 2025, 12:05 pm

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Stephens Annual Investment Conference and the Piper Sandler 37th Annual Healthcare Conference.

• 
  Ameresco to Participate at Upcoming Conferences5 November 2025, 9:05 pm

  FRAMINGHAM, Mass.--(BUSINESS WIRE)--Ameresco, Inc., (NYSE: AMRC), a leading energy infrastructure solutions provider, today announced that members of its management team will attend the following investor conferences: On November 12, 2025, Ameresco’s Vice President of Business Development, Federal Solutions, and Utility Infrastructure, Gregory Caplan, will host a fireside chat at 9:55am ET at Cantor’s Crypto & AI/Energy Infrastructure Conference. This event will take place at The Ritz-Carlt

• 
  CONMED Corporation Announces Third Quarter 2025 Financial Results5 November 2025, 9:05 pm

  LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Sales of $337.9 million increased 6.7% year-over-year as reported and 6.3% in constant currency. Domestic revenue increased 5.9% year-over-year. International revenue increased 7.8% year-over-year as reported and 6.8% in constant currency. Diluted net earnings per share (GAAP) were $0.09, compared to diluted net earnings pe

• 
  MindMed to Participate in Upcoming Investor Conferences5 November 2025, 12:01 pm

  NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences: Stifel 2025 Healthcare Conference Format: Presentation Date and Time: Wednesday, November 12, 2025 at 1:20 PM ET Location: New York, NY Webcast Link: Stifel 2025 H

• 
  Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress5 November 2025, 12:01 pm

  WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the third quarter ended September 30, 2025. “The Viridian team continues to deliver strong results, highlighted by the successful submission of our BLA for veligrotug, completing enrollment in both pivotal c

• 
  MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT0345 November 2025, 6:30 am

  LYON, France--(BUSINESS WIRE)---- $MAAT #ASH--MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034.

• 
  Catalent’s SMARTag® ADC Pipeline and New Enhanced Conjugates Offering Featured at 16th World ADC San Diego4 November 2025, 9:00 pm

  TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc. presented new advancements in its SMARTag® antibody-drug conjugate (ADC) technology at the 16th World ADC San Diego conference.

• 
  NMDP to Present Research Advancing Transplant Access and Cell Therapy Innovation at ASH 20254 November 2025, 4:03 pm

  MINNEAPOLIS--(BUSINESS WIRE)--NMDPSM, a global nonprofit leader in cell therapy, and CIBMTR® (Center for International Blood and Marrow Transplant Research®), will present groundbreaking research at the 67th American Society of Hematology (ASH) Annual Meeting from Dec. 6-9 in Orlando, Fla. The data underscore NMDP’s commitment to advancing cell therapy and improving access and outcomes for all patients. Among the accepted abstracts is an oral presentation from the ACCESS clinical trial (NCT0490

• 
  Opna Bio Announces 2025 ASH Presentations Highlighting Preclinical Data from Novel Protein Degrader Program and Updated Interim Data from Phase 1 Combination Study of OPN-2853 with Ruxolitinib in Advanced Myelofibrosis4 November 2025, 2:00 pm

  SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that it will have an oral and a poster presentation at the upcoming 67th Annual American Society for Hematology (ASH) conference, taking place December 6-9, 2025, in Orlando, FL. The presentations will focus on the company’s novel, multi-functional protein degrader program and OPN-2853, a bromodomain and extra

• 
  Flatiron Health Announces Research to Be Presented at the 2025 American Society of Hematology’s Annual Meeting &amp; Exposition4 November 2025, 2:00 pm

  NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition happening from December 6-9, 2025, in Orlando, Florida. Flatiron's real-world data and research capabilities are featured across multiple presentations, including 12 research acceptances spanning hematologic malignancies—from CAR T cell therapy delivery and outcomes to measurable residual disease (MRD) testing patterns and treatment equity across

• 
  Family Heart Foundation® Launches New Initiative to Increase Understanding and Screening for High Lipoprotein(a), the Most Common Genetic Risk Factor for Premature Cardiovascular Disease4 November 2025, 1:00 pm

  FERNANDINA BEACH, Fla.--(BUSINESS WIRE)-- #FindLpa--The Family Heart Foundation, the leading research, education and advocacy organization focused on genetic dyslipidemias, has launched the Lp(a) AW(a)RETM initiative to engage key U.S. healthcare stakeholders in advancing awareness, screening and diagnosis of high Lipoprotein(a) – also known as Lp(a). It is estimated that approximately 20% of the U.S. population has a genetic mutation for high Lp(a), yet only 1% in the general population, and 2% with esta

• CMS Establishes Coding Validating Sensus SRT for Treating Non-Melanoma Skin Cancer4 November 2025, 1:00 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that the Centers for Medicare & Medicaid Services (CMS) has published a distinct set of treatment codes specific to the use of superficial radiotherapy (SRT and IG-SRT) for non-melanoma skin cancer (NMSC). SRT-dedicated CPT codes refle

• United Therapeutics Corporation to Present at Upcoming Investor Conferences4 November 2025, 12:00 pm

  SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions at two upcoming investor conferences. Patrick Poisson, Executive Vice President, Strategic Development, will present at the UBS Global Healthcare Conference in Palm Beach, Florida on Monday, November 10, 2025, from 9:30 a.m. to 10:0

• 
  Summit Therapeutics to Present at Upcoming Investor Conferences4 November 2025, 12:00 pm

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at four upcoming investor conferences during the remainder of this year. Members of the Summit leadership team will participate in fireside chats and individual investor meetings at the following conferences: UBS Global Healthcare Conference in Palm Beach on Monday, November 10, 2025 at 3:30pm EST Jefferies Global Healthcare Conference in Lon

• 
  Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences4 November 2025, 12:00 pm

  WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in the following investor conferences in November and December. Jefferies London Global Healthcare Conference: Fireside Chat on Tuesday, November 18, 2025 at 1:00 p.m. GMT / 8:00 a.m. ET 8th Annual Evercore Healthcare Conf

• 
  MaaT Pharma Announces Positive Phase 3 Results Evaluating Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease Selected for Oral Presentation at ASH Congress 20253 November 2025, 5:00 pm

  LYON, France--(BUSINESS WIRE)---- $MAAT #ASH--MaaT Pharma Announces Positive Phase 3 Results Evaluating Xervyteg® (MaaT013) in aGvHD Selected for Oral Presentation at ASH Congress 2025.

• 
  Abcuro to Present Interim Phase 1 Data Evaluating Ulviprubart in Patients with T Cell Large Granular Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting3 November 2025, 2:32 pm

  NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a late-stage clinical biotechnology company developing potential first-in-class immunotherapies for the benefit of people living with debilitating and progressive rare autoimmune diseases and cancers, today announced that the Company will present interim data from the Phase 1/2 clinical trial evaluating the safety, tolerability, and hematological effect of ulviprubart in patients with T cell large granular lymphocytic leukemia (T-LGLL) who suffer fr

• 
  Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting3 November 2025, 2:31 pm

  WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting

• 
  Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies3 November 2025, 2:05 pm

  FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that five abstracts – one oral and four poster presentations – have been accepted for presentation at the 67th American Society of Hematology (ASH) 2025 Annual Meeting, to be held December 6-9, 2025 in Orlando, FL. The data feature new clinical and translational analyses of RYTELO (imetelstat) across l

• 
  Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting3 November 2025, 2:05 pm

  COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that more than 20 abstracts evaluating epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and B-cell non-Hodgkin’s lymphoma (NHL) subtypes, will be presented at the 67th Annual Meeting and Exposition of the American Society of Hematology (ASH), in Orlando, Florida, and online, December 6-9. Data from the epcoritamab development program will showcase its expan

• DoseMe Acquires Firstline to Build End-to-End Clinical Decision Support for Health Systems in the Global Fight Against Infectious Disease3 November 2025, 2:00 pm

  JUPITER, Fla. & VANCOUVER, British Columbia--(BUSINESS WIRE)--DoseMe, a global leader in model-informed precision dosing (MIPD) software and a portfolio company of Fairlong Capital, today announced the acquisition of Firstline, a leading clinical decision support platform utilized worldwide. Firstline enables clinicians to rapidly access local, evidence-based infectious disease treatment guidance, susceptibility patterns, and antimicrobial stewardship (AMS) resources. The combination of DoseMe

• 
  Qihan Biotech Announces Multiple Presentations at the 2025 American Society of Hematology (ASH) Annual Meeting3 November 2025, 2:00 pm

  HANGZHOU, China--(BUSINESS WIRE)--Qihan Biotech, a biotechnology company founded by Dr. Luhan Yang and Dr. George Church, is harnessing multiplex genome editing to develop off-the-shelf allogeneic cell therapies for patients with serious medical conditions. The company integrates advanced gene-editing technologies with scalable manufacturing to enable safe, effective, and globally accessible therapeutic solutions. At the upcoming 2025 American Society of Hematology (ASH) Annual Meeting, Qihan B

• 
  Orum Therapeutics Announces Presentation of Preclinical Data for ORM-1153 at the 2025 American Society of Hematology (ASH) Annual Meeting3 November 2025, 2:00 pm

  BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)-- #ADC--Orum Therapeutics Announces Presentation of Preclinical Data for ORM-1153 at the 2025 American Society of Hematology (ASH) Annual Meeting

• 
  Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences3 November 2025, 2:00 pm

  CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences

• 
  Orca Bio to Present New Clinical Data on Its High-Precision Cell Therapies at the 67th American Society of Hematology Annual Meeting3 November 2025, 2:00 pm

  MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio announces new clinical data on its high-precision cell therapies will be presented at the 67th American Society of Hematology Annual Meeting

• 
  PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting3 November 2025, 2:00 pm

  BOSTON--(BUSINESS WIRE)--PureTech to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at ASH Annual Meeting

• Sensus Healthcare Announces the Passing of Director Bill McCall31 October 2025, 12:00 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the passing of longtime friend of the Company and current Director William “Bill” McCall. Bill’s involvement with Sensus dates to 2009, when he played a key role in transforming the company from concept to reality. He led the Company’s ini

• 
  Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting31 October 2025, 12:00 pm

  BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present final results from the ALPHA-STAR Phase 1b/2 trial of navenibart in people living with hereditary angioedema (HAE) at the American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting, taking place November 6-10, 2025 in Orlando, Florida. Aleena Banerji, M.D.

• 
  Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 202531 October 2025, 11:00 am

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that results from the Phase III HARMONi-A trial, conducted in China and sponsored by our partner, Akeso, Inc. (“Akeso,” HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented as part of the Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2025) in National Harbor, Maryland (Washington D.C

• 
  QIAGEN Launches New Automated Sexual Assault Sample Processing Kit at ISHI 202530 October 2025, 9:05 pm

  GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the EZ2 DNA Investigator Sep&Prep Kit, a fully automated solution for processing sexual assault samples, at the upcoming International Symposium on Human Identification 2025 (ISHI) from November 3-6 in Palm Beach, Florida. Developed specifically for forensic laboratories, the EZ2 DNA Investigator Sep&Prep kit enhances the separation of sperm from n

• 
  Nuvation Bio to Participate in Upcoming Investor Conferences30 October 2025, 8:05 pm

  NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in three upcoming investor conferences, including fireside chats at two conferences: Jefferies Global Healthcare Conference on Wednesday, November 19, 2025,

• 
  NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors30 October 2025, 4:51 pm

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present research at ISLB 2025 showing high concordance between its RaDaR ST and RaDaR 1.0 MRD assays, plus four additional posters.

• 
  Allosite Therapeutics to Present Four Posters at American Society of Nephrology Kidney Week 202530 October 2025, 12:00 pm

  MIAMI--(BUSINESS WIRE)--Allosite Therapeutics, a biotechnology company discovering and developing innovative integrin therapies for kidney diseases and other immunologic conditions, today announced that the company will present four posters at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, TX, November 5–9, 2025. Presentations will include new data highlighting the activity of ONT01, a first-in-class allosteric agonist of integrin αMβ2, demonstrating significant reduction

• 
  PanGIA Biotech to Present Four Abstracts at ISLB 2025 Showcasing Multi-Disease Detection Capabilities30 October 2025, 11:30 am

  MIAMI--(BUSINESS WIRE)-- #ISLB2025--PanGIA Biotech announced today four of its abstracts were accepted for presentation at the 7th Annual Congress of Liquid Biopsy (ISLB 2025)¹, November 1–3 in Orlando, Florida. This recognition reflects PanGIA Biotech’s broad capabilities and active participation within the liquid-biopsy community. The presentations describe how PanGIA Analysis System (PAS) detects biomolecular patterns associated with multiple diseases beyond oncology. This evolution from single-disease

• 
  KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma &amp; Immunology 2025 Annual Scientific Meeting30 October 2025, 11:00 am

  FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of one abstract for late-breaking oral presentation and three for poster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting taking place in Orlando, Florida from November 6–10, 2025. The lake-breaking oral presentation will take place during Distinguished Industry & Late-breaking Oral Abstracts – Se

• 
  Outcomes Introduces Integrated Vaccines Module to Streamline Immunization Workflows and Reporting29 October 2025, 6:00 pm

  ORLANDO, Fla.--(BUSINESS WIRE)--Outcomes® announced today that it has recently launched its Vaccines Module, one of four Premium Modules introduced this year, delivering a fully integrated and modernized immunization experience for pharmacies. The module replaces the legacy PrescribeWellness Vaccines solution, bringing vaccine opportunity identification and state IIS (Immunization Information System) reporting natively into the Outcomes platform. Built directly into the Outcomes platform, the V

• 
  UniTriTeam Wins Magic ClinTech Stack Award at SCRS Global Site Solutions Summit in Florida29 October 2025, 12:30 pm

  SAN DIEGO--(BUSINESS WIRE)--UniTriTeam wins Magic ClinTech Stack Award for innovation in clinical tech transforming patient care, workflows, and outcomes.

• 
  Butterfly Network to Participate at UBS Global Healthcare Conference 202529 October 2025, 12:05 pm

  NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)---- $BFLY #POCUS--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that Joseph DeVivo, President, Chief Executive Officer & Chairman and Megan Carlson, Senior Vice President & Interim Chief Financial Officer will participate in a fireside chat and host one-on-one investor meetings at the UBS Global Healthcare Conference. The fireside cha

• 
  Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences28 October 2025, 8:05 pm

  SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: UBS Global Healthcare Conference Fireside Chat: Monday, November 10, 2025 at 2:00 p.m. Eastern Time in Palm Beach Gardens, FL Jefferies Global Healthcare Conference in London Presentation: Tuesday, November 18, 2025 at 8:30 a.m. Greenwich Mean Time in London Live webcasts of each will be accessible on the company’s website, acadia.com, under the i

• 
  While Premiums Climb, Impact Health Sharing Holds Rates Steady and Adds New Perks at No Extra Cost28 October 2025, 4:17 pm

  DAVIE, Fla.--(BUSINESS WIRE)-- #enhancedhealthcare--As healthcare premiums rise across the country ahead of open enrollment, Impact Health Sharing is taking a different approach: holding monthly share rates steady for the fifth consecutive year while expanding member perks, at no additional cost. Members of Impact Health Sharing save up to 50% each month on average compared to traditional insurance and have collectively shared and saved more than $275 million in eligible medical bills since 2020. Now, the organizati

• 
  AHF Webinar Panel Discussion—Equity on the Line: The PABS Annex and the Future of the Pandemic Agreement28 October 2025, 3:37 pm

  MIAMI--(BUSINESS WIRE)-- #COVID19--AIDS Healthcare Foundation (AHF), in collaboration with the University of Miami Public Health Policy Lab, will cohost a webinar, “Equity on the Line: The PABS Annex and the Future of the Pandemic Agreement,” on Wednesday, October 29, 2025 at 10:00 AM EDT, virtually via Zoom. Register here. The Intergovernmental Working Group (IGWG) on the WHO Pandemic Agreement has entered a decisive phase, with Member States facing a compressed timeline to finalize the Pathogen Access a

• 
  Revvity to Present at Upcoming Investor Conferences28 October 2025, 12:00 pm

  WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: UBS Global Healthcare Conference 2025 Monday, November 10, 2025 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Jefferies 2025 London Healthcare Conference Tuesday, November 18, 2025 2:00 p.m. GMT – Max Krakowiak Citi's 2025 Global Healthcare Conference Tuesday, December 2, 2025 9:00 a.m. ET – Prahlad Singh, president and chief execu

• 
  Found Health Launches GLP-1 Microdosing Program for Early Metabolic Dysfunction28 October 2025, 12:00 pm

  MIAMI--(BUSINESS WIRE)--Found, the doctor-designed telehealth platform specializing in personalized weight care since 2019, today announced the launch of its GLP-1 Microdosing Program. The program addresses a critical gap in preventive care: patients with early metabolic dysfunction often wait years for treatment until their condition worsens to meet traditional prescribing thresholds. "For too long, healthcare has ignored the sophisticated signals our bodies send about metabolic health—and wor

• 
  NeoGenomics Reports Third Quarter 2025 Results28 October 2025, 11:05 am

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its third-quarter results for the period ended September 30, 2025.

• 
  Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by “Championing the Missions that Matter™”28 October 2025, 4:01 am

  TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc., a leading global contract development and manufacturing organization, today unveiled its new corporate brand, marking a strategic evolution that underscores the company’s commitment to delivering unparalleled customer service and its focus on “championing the missions that matter.” The new approach reflects Catalent’s dedication to helping its pharmaceutical, biotech and consumer health customers bring their life-enhancing and life-changing solution

• Sensus Healthcare to Report Third Quarter 2025 Financial Results and Hold Business Update Conference Call on November 623 October 2025, 12:00 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the third quarter of 2025 on Thursday, November 6, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer q

• 
  Summit Therapeutics Raises $500 Million in Private Placement22 October 2025, 12:00 pm

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Company has accepted offers from multiple leading biotech institutional and individual investors to purchase an aggregate of approximately 26.68 million shares of the Company’s common stock at $18.74 per share, the closing price on Tuesday, October 21, 2025, for aggregate gross and net proceeds to the Company of approximately $500 million. Robert W. Duggan, the Company’s C

• 
  AHF Webinar Panel Discussion—Antimicrobial Resistance – A Global Health Security Crisis21 October 2025, 6:26 pm

  MIAMI--(BUSINESS WIRE)-- #AMR--AIDS Healthcare Foundation (AHF), in collaboration with the University of Miami Public Health Policy Lab, will cohost a webinar, “Antimicrobial Resistance – A Global Health Security Crisis,” on Thursday, October 23, 2025 at 10:00 AM EDT, virtually via Zoom. Register here. This timely webinar will confront one of the most urgent yet underestimated threats to global health: antimicrobial resistance (AMR). Responsible for nearly five million deaths each year, AMR jeopardize

• 
  Cade Prize for Inventivity Announces 2025 Winners21 October 2025, 3:50 pm

  GAINESVILLE, Fla.--(BUSINESS WIRE)-- #CadePrize--Named after Dr. James Robert Cade, the lead inventor of Gatorade, the Cade Prize for Inventivity celebrates early-stage companies with innovative ideas and commercial potential. On Tuesday, October 14, fifteen finalist teams gathered at the Cade Museum for Creativity and Invention for the final rounds of judging and the awards ceremony. Quornix, a biotechnology startup from Bloomington, Ind., won the Grand Prize for developing pioneering therapeutic technolog

• 
  STARLIMS Launches QM Essentials LIMS, the Best Cloud LIMS for SMB Batch Manufacturing21 October 2025, 1:13 pm

  HOLLYWOOD, Fla.--(BUSINESS WIRE)-- #LIMS--STARLIMS, a global leader in Laboratory Information Management Systems (LIMS) and informatics solutions, today announced Quality Manufacturing (QM) Essentials, a new cloud-based LIMS developed for small and mid-sized (SMB) batch manufacturers to bring products to market quickly and more cost-effectively. The launch reflects STARLIMS’ commitment to meeting the unique needs of smaller batch manufacturing organizations who need the power of a LIMS without the cost

• 
  Unified Women’s Healthcare’s Affiliates Elevate Menopause Care as Key Component to Closing the Midlife Care Gap21 October 2025, 1:05 pm

  TAMPA, Fla.--(BUSINESS WIRE)--Unified Women’s Healthcare (Unified), through its affiliated physicians, is setting the standard for how women receive menopause treatment. Through a combination of in-person visits and Unified’s telehealth-first menopause platform, Gennev, patients experiencing menopause symptoms, such as reduced energy, cognitive shifts, hot flashes and sleep disruption, receive the care they need at a rate 20% higher than the national average. “We are seeing a real shift in how

• 
  Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency21 October 2025, 12:00 pm

  SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, announced today that it has regained full compliance with NYSE American’s continued listing standards and is positioning the Company to focus exclusively on advancing its lead clinical program. NYSE Compliance Regained Effective October 20, 2025, the NYSE American notified Oragenics that the Comp

• 
  Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)20 October 2025, 11:30 am

  BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicines, today announced the presentation of two-year data from the FALCON study, a prospective natural history study in people with Autosomal Dominant Optic Atrophy (ADOA) (n=47). Results were presented at the 2025 American Academy of Ophthalmology (AAO) Annual Meeting and provide important insights into ADOA,

• 
  Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 202520 October 2025, 10:45 am

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the third quarter ended September 30, 2025. Planned BLA Submission for Ivonescimab in Q4 2025 Today, Summit announces that, based on the results of the HARMONi clinical trial, it plans to submit a Biologics License Application (BLA) in order to seek approval for ivonescimab plus chemotherapy for this proposed in

• 
  Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China19 October 2025, 2:30 pm

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented today as part of the Presidential Symposium at the European Society for Medical Oncology 2025 Congress (ESMO 2025) in Berlin, Germany. The

• 
  Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months18 October 2025, 6:30 pm

  SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- #AAO2025--Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced positive 12 month results from the company’s Phase 1/2 CLARA trial, which evaluated the safety, efficacy and tolerability of AURN001 (neltependocel [human corneal endothelial cells] in combination with Y-27632 rho-kinase inhibitor) in patients with corneal edema secondary to corneal endothelial dysfunction.

• 
  Humata Health to Provide Access to Prior Authorization Technology Through Microsoft Dragon Copilot17 October 2025, 7:22 pm

  WINTER PARK, Fla.--(BUSINESS WIRE)--Humata Health today announced plans to make its AI-powered prior authorization technology available with Microsoft Dragon Copilot. By delivering enhanced capabilities within this ambient-powered AI clinical assistant, Humata Health will enable clinicians to automate and streamline crucial prior authorization tasks, ultimately reducing provider burden and accelerating patient access to appropriate care. Humata Health will be able to offer its technology within

• 
  Massive Bio Calls on Congress to Classify ClinicalTrials.gov as Essential Infrastructure Amid Government Shutdown17 October 2025, 4:59 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--During the ongoing government shutdown, ClinicalTrials.gov, the nation’s central registry for medical research and clinical studies, has gone offline, leaving millions of patients with cancer and other serious diseases unable to search for potentially life-saving clinical trials. "This should alarm every American," said Dr. Arturo Loaiza-Bonilla, Co-Founder and Chief Medical & AI Officer of Massive Bio, a company recognized by the White House Cancer Moonsh

• 
  Parabilis Medicines Presents Clinical Data Demonstrating First-Ever Drugging of Key Cancer Driver with FOG-00117 October 2025, 2:00 pm

  CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced at the ESMO Congress 2025 the first-ever clinical data showing that its investigational FOG-001 therapy has successfully drugged β-catenin:TCF – a key cancer-driving node in the Wnt/β-catenin pathway, until now considered “undruggable.” In the ongoing Phase 1/2 trial of FOG-001 in patients with a range of

• 
  Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer17 October 2025, 11:00 am

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the expansion of its Phase III clinical development program of the novel, potential first-in-class investigational bispecific antibody, ivonescimab, into colorectal cancer (CRC) with the initiation of the global Phase III HARMONi-GI3 trial. Summit is starting a Phase III clinical study, HARMONi-GI3, to evaluate ivonescimab plus chemotherapy compared to bevacizumab plus chemotherapy

• 
  Two Odyssey Marine Exploration Autonomous Benthic Mini Landers Successfully Deployed in the Cook Islands’ EEZ16 October 2025, 1:00 pm

  TAMPA, Fla.--(BUSINESS WIRE)---- $OMEX--Odyssey Marine Exploration, Inc. (NASDAQ: OMEX), an ocean exploration leader engaged in critical mineral resource development, today announced the successful deployment of its two Autonomous Benthic Mini Landers (ABML) in the Cook Islands’ exclusive economic zone (EEZ). This milestone marks the first deep-sea deployment of custom systems engineered by Develogic GmbH for Odyssey. The ABMLs will collect in situ environmental data to help build long-term datasets on b

• 
  Vistagen to Present at The Menopause Society 2025 Annual Meeting16 October 2025, 12:30 pm

  SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present data on its investigational pherine nasal spray, PH80, at The Menopause Society 2025 Annual Meeting in Orlando, Florida, on Thursday, October 23, 2025. PH80 is Vistagen’s novel, non-systemic, non-hor

• 
  Heru Surpasses 1 Million Eyes Tested, Cementing Leadership in AI-Powered Vision Diagnostics16 October 2025, 11:00 am

  MIAMI--(BUSINESS WIRE)-- #automation--Heru, the leader in AI-powered vision diagnostics, today announced it has surpassed a landmark achievement of one million eyes tested on its wearable platform. This significant milestone underscores the company's accelerated adoption across the United States and solidifies its position as the market leader in modernizing the standard of care for eye exams. Born out of the Bascom Palmer Eye Institute, the #1 ranked eye hospital in the nation at UHealth — the University of

• 
  Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2025 Financial Results15 October 2025, 9:00 pm

  OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”, “Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2025. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2025 were $7.83 million compared to $8.07 million for the third quarter of fiscal 2024, a 3% decrease. Net Income The Company reported net i

• 
  PolyActiva to Present Advancements in Next-Generation Ocular Micro-Implant Technology at Eyecelerator® @ AAO 202515 October 2025, 12:00 pm

  FORT WORTH, Texas & MELBOURNE, Australia--(BUSINESS WIRE)--PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, today announced that Michael Brubaker, Ph.D., Chief Scientific Officer, will present a corporate overview at Eyecelerator® @ the American Academy of Ophthalmology (AAO) 2025 Annual Meeting on Thursday, October 16, 2025, in Orlando, Florida. PolyActiva’s presentation will highlight th

• 
  Summit Therapeutics to Host ESMO Data Update &amp; Third Quarter Earnings Call on October 20, 202515 October 2025, 11:00 am

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October 20, 2025, before the market opens. The ESMO data relates to the planned disclosure of the HARMONi-6 clinical trial data. As a reminder, the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispeci

• 
  Humana Foundation Expands National Efforts to Improve Seniors’ Emotional Health14 October 2025, 12:00 pm

  LOUISVILLE, Ky.--(BUSINESS WIRE)--The Humana Foundation, the philanthropic arm of Humana Inc. (NYSE: HUM) for the past 44 years, today announced its ambition to become a national leader in addressing seniors’ emotional health. More than one in four seniors (29%) report being socially isolated, increasing their risk of dementia (by 50%) and self-harm. The Foundation’s 2025 program and research grants—totaling over $12 million—tackle loneliness, illness and other community and cultural drivers of

• 
  NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 202514 October 2025, 11:05 am

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will share at ESMO 2025 how its RaDaR ST MRD assay can support pharmaceutical partners across oncology research and clinical trials.

• 
  Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting14 October 2025, 11:00 am

  ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held October 18-20, 2025, in Orlando, Florida. Glaukos will be exhibiting onsite at booth #2921. Key Glaucoma

• 
  GeneDx to Partner with Florida’s Sunshine Genetics Network, Launching Nation’s First State-Backed Genomic Newborn Screening Program13 October 2025, 12:00 pm

  GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced its involvement in the Sunshine Genetics Act, establishing the nation’s first state-backed genomic newborn screening program.

• 
  Smart Meter Secures SOC 2 Type II Certification for Third Consecutive Year, Reinforcing Leadership in Secure Remote Patient Monitoring9 October 2025, 1:00 pm

  TAMPA, Fla.--(BUSINESS WIRE)--Smart Meter, the leading provider of cellular-enabled remote patient monitoring (RPM) solutions, proudly announces its successful attainment of SOC 2 Type II certification for the third consecutive year—a testament to its unwavering commitment to data security, operational excellence, and patient privacy. This prestigious certification, conducted by Schellman, a top-tier SOC 2 audit firm, confirms that Smart Meter’s systems and processes consistently meet the highe

• Ascenta Capital Announces Final Close of $325 Million Inaugural Fund to Back Development-Stage Biotechs9 October 2025, 1:00 pm

  WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Ascenta Capital (“Ascenta”), a venture firm investing in multi-medicine development-stage biotechnology companies, today announced the $325 million close of its inaugural fund (the “Fund”). Ascenta was founded in 2023 by Evan Rachlin, MD, and Lorence Kim, MD, who bring deep biotech operating and investment expertise. The firm leads or co-leads investments in multi-medicine biotech companies at the early stages of human trials. Ascenta’s 14-person team com

• 
  Elevate Organic Launches First-Ever Organic, Clinically Studied Shatavari Supplement9 October 2025, 12:45 pm

  JUPITER, Fla.--(BUSINESS WIRE)--Elevate Organic launches SRI-81™ Shatavari & ROC™ KSM-66® Ashwagandha supplements, featuring first-to-market capsules and gummies backed by science.

• 
  Trividia Health, Inc. Initiates Voluntary Recall of Limited Number of TRUE METRIX® Blood Glucose Meters7 October 2025, 7:07 pm

  FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Trividia Health, Inc., announced today that it is initiating a voluntary recall of a limited number of TRUE METRIX® Self-Monitoring Blood glucose meters co-branded under the Good Neighbor Pharmacy® brand and distributed in the United States. The company has determined that 601 TRUE METRIX® Meters, lot number KD0746, manufactured September 4, 2025 and distributed September 8, 2025, through September 16, 2025, may have the potential for defective LCD displa

• 
  Hesperos and Bayer Consumer Health Develop First Human-on-a-Chip® Model of Stress-Induced Cognitive Dysfunction7 October 2025, 5:00 pm

  ORLANDO, Fla.--(BUSINESS WIRE)-- #BiotechNews--Hesperos, Inc. (Hesperos), a global leader focused on improving preclinical drug development, food, cosmetic, and chemical testing with its Human-on-a-Chip® (HoaC) single- and multi-organ systems platform, is pleased to announce the publication of a new peer-reviewed study, developed in collaboration with Bayer Consumer Health. The study introduces the first human-relevant microphysiological system (MPS) capable of modeling central nervous system (CNS) stress res

• 
  Sightview to Unveil New Design, User Experience at AAO 20257 October 2025, 1:15 pm

  DURHAM, N.C.--(BUSINESS WIRE)-- #EHR--Sightview’s new UI brings workflow and efficiency enhancements, developed and tested with optometrists, ophthalmologists and opticians.

• 
  Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development7 October 2025, 12:30 pm

  SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced a strategic collaboration with Receptor.AI, an artificial intelligence-driven drug profiling company, to accelerate the potential development of an expanded pharmaceutical-candidate portfolio for potential conditions affecting brain health. This partnership represents a significant milestone in Oragenics' ev

• 
  DemeRx Awarded $1.7 Million National Institutes of Health Grant to Advance Potential First-in-Class Neuroplastogen Drug Candidate DMX-1001 for Alcohol Use Disorder (AUD)7 October 2025, 11:45 am

  MIAMI--(BUSINESS WIRE)--DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, today announced it was awarded a $1.7 million Small Business Innovation Research (SBIR) Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) at the National Institutes of Health (NIH). This funding will help advance DemeRx's promising neuroplastogen drug candidate, DMX-1001 (noribogaine), through the necessary IND-enabling studies and toward Pha

• 
  Redwire Announces CFO Retirement and Plan for Succession7 October 2025, 11:30 am

  JACKSONVILLE, Fla.--(BUSINESS WIRE)--Redwire Corporation (NYSE: RDW) (“Redwire” or the “Company”), a global leader in space and defense technology solutions, today announced that Jonathan Baliff, the Company’s Chief Financial Officer, will retire effective November 30, 2025. In connection with Mr. Baliff’s retirement, the Board plans to appoint Chris Edmunds, who is currently serving as the Company’s Senior Vice President and Chief Accounting Officer, to succeed Mr. Baliff. Mr. Baliff will serv

• 
  NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 20257 October 2025, 11:05 am

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its third quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, Oct. 28, 2025.

• 
  Pharmacists Strained as Diabetes Cases Rise, and Patients are Paying the Price7 October 2025, 11:00 am

  ST. PETERSBURG, Fla.--(BUSINESS WIRE)--To date, the availability of a pharmacist behind the counter of the local retail pharmacy has been an important resource for people living with chronic conditions like diabetes. However, as the number of diabetes patients continues to grow and pharmacy workloads increase, pharmacists are saying they lack the time and resources to provide the level of education and coaching patients need to stay healthy. According to a new report engaging more than 100 phar

• 
  Pridopidine Pivotal Phase 3 ALS Study Unveiled at NEALS 2025 Annual Meeting6 October 2025, 12:00 pm

  NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain--(BUSINESS WIRE)--Prilenia Therapeutics B.V. and Ferrer today announced the presentation of their planned pivotal Phase 3 study of pridopidine in Amyotrophic Lateral Sclerosis (ALS) at the upcoming Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) 2025 Annual Meeting, Florida, October 7-10, 2025. “The opportunity to potentially bring a much-needed new therapy for a disease as intractable as ALS is exciting and daunting in equal m

No Feed

No Feed

No Feed

No Feed

No Feed